Summit Therapeutics Stock Rises 7% After AstraZeneca Strategic Investment

Summit Therapeutics (NasdaqGM: SMMT) announced a clinical collaboration and a $2B investment from AstraZeneca to develop cancer treatments, including ivonescimab. The partnership supports Summit's development plans without changing ownership. Key catalysts include an upcoming FDA decision on ivonescimab's BLA, with projected revenue of $1.3B and earnings of $223M by 2029.

Summit Therapeutics (SMMT) stock rose 6.23% after AstraZeneca invested $2B via convertible preferred stock, valuing SMMT at a 10% premium. The deal includes clinical collaboration on ivonescimab, with promising trial results. SMMT has no significant revenue, a net loss of $231.8M, and $238.6M in cash. Jefferies upgraded SMMT to Buy with a $25 price target.

Citigroup maintained a Buy rating on Summit Therapeutics (SMMT) and raised its price target to $43.00 from $40.00. The company has a market cap of $13.08 billion and a GF Score of 34/100, indicating challenges in profitability and growth. Insider activity shows no recent buys or sells.

Summit Therapeutics (SMMT) rose 5.7% after AstraZeneca agreed to invest $2 billion in convertible preferred shares at $18.36 per share. The companies will collaborate on cancer studies, including testing ivonescimab with AstraZeneca's treatments. Recent Phase III updates and FDA review may have bolstered investor confidence.

Summit Therapeutics (SMMT) shares rose 22% after AstraZeneca (AZN) agreed to invest $2B in the company to accelerate development of ivonescimab. The deal includes a strategic equity investment and clinical-development arrangements. AstraZeneca will hold about 12% of Summit's outstanding common stock. Ivonescimab is a bispecific antibody targeting PD-1 and VEGF, with an FDA decision on its approval expected by Nov. 14, 2026.

Summit Therapeutics (SMMT) shares surged 17% premarket after AstraZeneca (AZN) agreed to invest $2B in Summit's equity, acquiring 12% of its outstanding stock. The companies will collaborate on clinical trials for cancer treatments, sharing costs. Ivonescimab, Summit's drug, is approved in China and under FDA review.